Abstract # 1122 Phase I Trial Of The Farnesyltransferase Inhibitor Tipifarnib (R155777) In Combination With Radiotherapy In Patients With Newly Diagnosed Glioblastoma.

Presenter: Cohen-Jonathan Moyal, Elizabeth

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

About the Presenter:
Cohen Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ, Prats H, Daly-Schveitzer N, Favre G. Cancer Res. 1997 57 : 1364-70. Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C., Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation Int J Cancer 2002, 100, 43-48 Ader I, Delmas C, Bonnet J, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene 2003 ; 22:8861-9. Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 2002; 21: 5998-6006 -Delmas C, End D, Rochaix P., Favre G, Toulas C, Cohen-Jonathan E The farnesyltransferase inhibitor R115777 reduces hypoxia and MMP-2 expression in human glioma xenograft . Clin.Cancer.Res. . 2003;9:6062-8. Skuli, N.,Monferran S, Delmas C, Lajoie-Mazenc I, Favre G, Toulas C, Cohen-Jonathan E. Activation of RhoB by hypoxia controls HIF-1alpha stabilization through GSK-3 in U87 glioblastoma cells. Cancer Res.2006 66: 482-489
Contact the presenter at: moyal.elizabeth@claudiusregaud.fr

E. L. Cohen-Jonathan Moyal*, A. Laprie*, M. Poublanc*, F. Dalenc*, C. Toulas*, B. Alaux*. , Institut Claudius Regaud, Toulouse, France,

Author Disclosure:
E.L. Cohen-Jonathan Moyal, None; A. Laprie, None; M. Poublanc, None; F. Dalenc, None; C. Toulas, None; B. Alaux, None.

E-mail a friend about this abstract:
Enter email address:   

Abstracts Main Page | Logout